Press Releases
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Feb 12, 2014
Eisai Inc. announced today that its subsidiary Eisai Laboratorios Ltda has filed for the marketing authorization of BELVIQ as a treatment for...
-
Feb 10, 2014Number of Insured Commercial Lives in the U.S. with Coverage for BELVIQ® Now Exceeds 50 Percent
Eisai Inc. reported today that it has secured improved patient access of BELVIQ® (lorcaserin HCl) with two leading healthcare benefit...
-
Jan 2, 2014FYCOMPA is the First and Only FDA-Approved Non-Competitive AMPA Glutamate Receptor Antagonist
Eisai Inc. announced today that FYCOMPA™ (perampanel) CIII will be available to eligible patients by prescription in the U.S. beginning...
-
Dec 5, 2013
Today, Eisai Inc. announced that 16 abstracts highlighting new data analyses on FYCOMPA (perampanel) will be presented at the 67th annual...
-
Dec 3, 2013Eisai Tackles Stigma Associated With Epilepsy Through Support Of Comic Book Addressing The Condition"Medikidz Explain Epilepsy" Aims to Help Children Better Understand the Disease
Eisai Inc., a leader in the epilepsy community, is proud to announce the availability of a first-of-its-kind comic book in the U.S. designed to...